MetaCap

BeOne Medicines (ONC) vs Takeda Pharmaceutical (TAK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Takeda Pharmaceutical (TAK) has outperformed BeOne Medicines (ONC) over the past year, gaining 52.2% versus a gain of 12.4%. Over five years, TAK leads with a +60.9% price change compared with +12.4% for ONC. Takeda Pharmaceutical is the larger company by market cap ($69.55 billion vs $44.66 billion), about 1.6 times the size.

On valuation, BeOne Medicines trades at a lower forward P/E (35.9x vs 41.1x for Takeda Pharmaceutical). Takeda Pharmaceutical pays a dividend yielding 927.88%, while BeOne Medicines does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ONC+12.43%TAK+52.24%
+56%+14%-29%
Nov 21, 20251 yearNov 20, 2026
ONC+7.24%TAK+55.39%
+61%-5%-70%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ONC versus TAK key metrics
MetricONCTAK
Share price$390.94$21.77
Market cap$44.66B$69.55B
1-day change-2.19%+1.68%
YTD return+28.68%+39.64%
1-year return+12.43%+52.24%
5-year return+12.44%+60.90%
P/E ratio (TTM)50.12311.00
Forward P/E35.9341.08
EPS (TTM)$7.80$0.07
Dividend yield0.00%927.88%
Annual dividend$0.00$202.00
Revenue (latest FY)$5.34B—
Revenue growth (YoY)+40.23%—
Net income (latest FY)$286.93M—
Gross margin87.49%—
Operating margin8.37%—
Net margin5.37%—
52-week high$424.73$22.07
52-week low$253.95$14.16
Distance from 52-week high-7.96%-1.36%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+20.03%+12.68%
Average volume392.74K2.73M
Shares outstanding105.38M3.19B
Employees12,00047,029
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TAK has outperformed ONC by 39.8 percentage points over the past year.
  • Takeda Pharmaceutical trades at a higher earnings multiple (311.0x vs 50.1x trailing P/E).
  • Takeda Pharmaceutical offers a meaningfully higher dividend yield (927.88% vs 0.00%).

About BeOne Medicines

ONC stock →

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees

About Takeda Pharmaceutical

TAK stock →

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.

Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees

ONC vs TAK FAQ

Which is bigger, BeOne Medicines or Takeda Pharmaceutical?

Takeda Pharmaceutical (TAK) is larger, with a market capitalization of $69.55B compared with $44.66B for BeOne Medicines (ONC).

Which stock has performed better over the past year, ONC or TAK?

TAK returned +52.24% over the past 12 months, compared with +12.43% for ONC (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ONC or TAK?

ONC has the lower trailing P/E at 50.1, versus 311.0 for TAK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, BeOne Medicines or Takeda Pharmaceutical?

Takeda Pharmaceutical pays a dividend yielding 927.88%, while BeOne Medicines does not currently pay a regular dividend.

Are BeOne Medicines and Takeda Pharmaceutical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons